NSCLC, FDA and Tagrisso
In less than a month, from August 20 to September 19, amivantamab (Ami; Rybrevant, Johnson & Johnson) received 2 approvals ...
The US Food and Drug Administration (FDA) has approved osimertinib (Tagrisso, AstraZeneca Pharmaceuticals) for the treatment ...
Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...
Olomorasib with pembrolizumab in the first-line showed a 77% overall response rate in patients with KRAS G12C–mutated ...
Panelists discuss how HER2-directed therapies in non–small cell lung cancer (NSCLC) are evolving, with experts examining the distinction between HER2 mutation and expression, evaluating the efficacy ...
The China-based trial enrolled 398 patients who were randomised to the ivonescimab and Keytruda arms at a one-to-one ratio.
NKT2152 makes strides in RCC, the amivantamab/chemotherapy combination receives approval for EGFR-mutant NSCLC, and experts discuss the future of AML. We also highlight the approval of the 420-mg dose ...
Patients with stage I NSCLC who receive stereotactic body radiotherapy rarely experience acute toxicities or 90-day mortality ...
Treatment of non-small cell lung cancer (NSCLC) depends on the stage you're in and can include chemotherapy, surgery, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback